←
Herbert Wertheim Cancer Institute Research1,197 posts
Herbert Wertheim Cancer Institute Research avatar✓

Herbert Wertheim Cancer Institute Research ✓

@MiamiCancerInst

Providing quality cancer care in South Florida and aiming for innovative research excellence, part of @BaptistHealthSF Formerly Miami Cancer Institute

◷ Joined October 2022▧ 416 Photos and videos
Toni Choueiri, MD avatar
⟳ Herbert Wertheim Cancer Institute Research retweeted
Toni Choueiri, MD@DrChoueiri·Nov 5

New in @TheLancetOncol : outcomes for patients with #RCC brain metastases are changing. In 1,049 patients, median OS was 20 months—up from 9.6–12 months in historical cohorts. Updated Renal GPA predicts survival from 4.8 to 51.2 months. Important message: brain metastases should not automatically exclude patients from clinical trials. Proud to contribute to this international effort led by Paul Sperduto and Minesh Mehta. thelancet.com/journals/lanon… @RifRahmanMD @SanjayAnejaMD @Luke_Pike_MD @TonyWangMD @SteveBraunstein @TugceKutukMD @Rrkotecha @DukeCancer @DukeRadOnc @MiamiCancerInst @BaptistHealthSF

Post attachmentPost attachmentPost attachment
Herbert Wertheim Cancer Institute Research avatar
Herbert Wertheim Cancer Institute Research@MiamiCancerInst·Nov 2

Advances in prostate cancer imaging and treatment are changing clinical decision-making. From MRI-guided targeted biopsies to PSMA imaging and focal therapies, emerging technologies are helping physicians better characterize disease, refine risk stratification and weigh oncologic control against functional outcomes. Baptist Health urologic surgical oncologist Manuel Ozambela Jr., M.D., shares how these advances are shaping a more individualized approach to prostate cancer care. Explore the clinical insights: bapth.lt/3X2CR67.

Post attachment
Herbert Wertheim Cancer Institute Research avatar
Herbert Wertheim Cancer Institute Research@MiamiCancerInst·Oct 30

Could oral toxicities be affecting patients’ ability to stay on cancer treatment? New research led by Baptist Health’s Alessandro Villa, D.D.S., Ph.D., M.P.H., examines oral complications associated with antibody-drug conjugates (ADCs), including differences in toxicity patterns between TROP2- and HER2-directed therapies. Explore the findings and their implications for toxicity monitoring and supportive care in oncology: bapth.lt/3WcFH8w.

Post attachment